- $1.20bn
- $947.90m
- $655.35m
Annual cashflow statement for Novocure, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -58.4 | -92.5 | -207 | -169 | -136 |
| Depreciation | |||||
| Non-Cash Items | 102 | 103 | 93.2 | 135 | 87.7 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 29 | 9.58 | 29.6 | -4.3 | -15.1 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Other Assets | |||||
| Change in Accrued Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | 82.8 | 30.8 | -73.3 | -26.4 | -49 |
| Capital Expenditures | -24.2 | -21.4 | -27.1 | -42.9 | -26.6 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -121 | -119 | 211 | -97.4 | 464 |
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -145 | -140 | 184 | -140 | 437 |
| Financing Cash Flow Items | — | — | — | — | -0.146 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 25.7 | 15.5 | 15.8 | 90.3 | -451 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -36.6 | -93.8 | 127 | -76.5 | -62.7 |